QFRIA
Live / Applied — Fourth extension granted (statement of use) (as of 12 Feb 2026)
What this means for you
Not registered yet, but its 23 Nov 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97690355
- Mark type
- Stylized text
- Filed
- 23 Nov 2022
- Published for opposition
- 25 Jul 2023
- Attorney of record
- MARILYN F. KELLY
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for human use for the treatment and prevention of cancer, auto-immune diseases, leukemia, lymphoma, multiple myeloma, autoinflammatory disease and tumors; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of cancer and cytokine inhibitory drugs; pharmaceutical and biological preparations for human use for immunotherapy, namely, T cell therapy; pharmaceutical preparations for human use, namely, stem cells for medical or clinical use, all the foregoing excluding pharmaceutical preparations for the treatment of hemophilia
Owner
- Bristol-Myers Squibb Company, Princeton, NJ, US
- Bristol-Myers Squibb Company, New York, NY, US
Prosecution history
- 09 Sept 2026 — SOU TEAS EXTENSION RECEIVED
- 12 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Feb 2026 — SOU EXTENSION 4 GRANTED
- 12 Feb 2026 — SOU EXTENSION 4 FILED
- 12 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 27 Aug 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 26 Aug 2025 — SOU EXTENSION 3 GRANTED
- 26 Aug 2025 — SOU EXTENSION 3 FILED
- 26 Aug 2025 — SOU TEAS EXTENSION RECEIVED
- 11 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 10 Mar 2025 — SOU EXTENSION 2 GRANTED
- 10 Mar 2025 — SOU EXTENSION 2 FILED
- 10 Mar 2025 — SOU TEAS EXTENSION RECEIVED
- 27 Aug 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 27 Aug 2024 — SOU EXTENSION 1 GRANTED